Last reviewed · How we verify
1 Cycle of Pembrolizumab
1 Cycle of Pembrolizumab is a Small molecule drug developed by Ismail Gögenur. It is currently in Phase 2 development. Also known as: Keytruda.
At a glance
| Generic name | 1 Cycle of Pembrolizumab |
|---|---|
| Also known as | Keytruda |
| Sponsor | Ismail Gögenur |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anaemia
- Nausea
- Diarrhoea
- Fatigue
- Decreased appetite
- Constipation
- Neutrophil count decreased
- Vomiting
- Rash
- Aspartate aminotransferase increased
- Pruritus
- Alanine aminotransferase increased
Key clinical trials
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (PHASE1)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1 Cycle of Pembrolizumab CI brief — competitive landscape report
- 1 Cycle of Pembrolizumab updates RSS · CI watch RSS
- Ismail Gögenur portfolio CI
Frequently asked questions about 1 Cycle of Pembrolizumab
What is 1 Cycle of Pembrolizumab?
1 Cycle of Pembrolizumab is a Small molecule drug developed by Ismail Gögenur.
Who makes 1 Cycle of Pembrolizumab?
1 Cycle of Pembrolizumab is developed by Ismail Gögenur (see full Ismail Gögenur pipeline at /company/ismail-g-genur).
Is 1 Cycle of Pembrolizumab also known as anything else?
1 Cycle of Pembrolizumab is also known as Keytruda.
What development phase is 1 Cycle of Pembrolizumab in?
1 Cycle of Pembrolizumab is in Phase 2.
What are the side effects of 1 Cycle of Pembrolizumab?
Common side effects of 1 Cycle of Pembrolizumab include Anaemia, Nausea, Diarrhoea, Fatigue, Decreased appetite, Constipation.
Related
- Manufacturer: Ismail Gögenur — full pipeline
- Also known as: Keytruda
- Compare: 1 Cycle of Pembrolizumab vs similar drugs
- Pricing: 1 Cycle of Pembrolizumab cost, discount & access